BioWorld December 2, 2025

Abbisko Therapeutics divulges new SMARCA2 inhibitors

BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Cancer Abbisko Therapeutics divulges new SMARCA2 inhibitors Dec. 2, 2025 Abbisko Therapeutics Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer. BioWorld ScienceCancerPatents